FC
AXSM icon

Financial Consulate’s Axsome Therapeutics AXSM Stock Holding History

Financial Consulate’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$206K Hold
1,217
– – 0.03% 149
2025
Q4 		$222K Hold
1,217
– – 0.03% 155
2025
Q3 		$148K Buy
+1,217
New +$137K 0.02% 187
2023
Q2 		– Sell
-5,220
Closed -$322K – 49
2023
Q1 		$322K Hold
5,220
– – 0.11% 95
2022
Q4 		$403K Hold
5,220
– – 0.14% 89
2022
Q3 		$233K Hold
5,220
– – 0.1% 106
2022
Q2 		$200K Buy
5,220
+355
+7% +$11.2K 0.09% 120
2022
Q1 		$201K Buy
+4,865
New +$151K 0.08% 127

Other funds holding AXSM

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Financial Consulate's AXSM Position: Q1 2026 in Review

Financial Consulate held its Axsome Therapeutics (AXSM) position steady in Q1 2026 at 1,217 shares worth $206K. The position accounts for 0.03% of the portfolio, ranked #149.

Financial Consulate first reported a position in AXSM in Q1 2022 and has held it in 8 quarters since. The position peaked at $403K in Q4 2022. 409 funds tracked by Wall St. Rank hold AXSM as of Q1 2026.

  • Financial Consulate held 1,217 shares of Axsome Therapeutics worth $206K as of Q1 2026.
  • Financial Consulate left its Axsome Therapeutics share count unchanged in Q1 2026.
  • Axsome Therapeutics made up 0.03% of Financial Consulate's portfolio in Q1 2026, its #149 holding.
  • Financial Consulate first reported a position in Axsome Therapeutics in Q1 2022 and has held it in 8 quarters since.
  • Financial Consulate's Axsome Therapeutics position peaked at $403K in Q4 2022.
  • 409 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q1 2026.

Based on Financial Consulate's 13F filing for Q1 2026, filed 21 Apr 2026.